Intest Res.  2020 Jan;18(1):134-135. 10.5217/ir.2019.00087.

Comparing histamine intolerance and non-clonal mast cell activation syndrome

• Cimolai N

• KMID: 2501376
• DOI: http://doi.org/10.5217/ir.2019.00087

Reference

1. Schnedl WJ, Lackner S, Enko D, Schenk M, Holasek SJ, Mangge H. Evaluation of symptoms and symptom combinations in histamine intolerance. Intest Res. 2019; 17:427–433.

2. Maintz L, Novak N. Histamine and histamine intolerance. Am J Clin Nutr. 2007; 85:1185–1196.

3. Schwelberger HG. Histamine intolerance: a metabolic disease? Inflamm Res. 2010; 59 Suppl 2:S219–S221.

4. Hamilton MJ, Hornick JL, Akin C, Castells MC, Greenberger NJ. Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol. 2011; 128:147–152.

5. Cardet JC, Castells MC, Hamilton MJ. Immunology and clinical manifestations of non-clonal mast cell activation syndrome. Curr Allergy Asthma Rep. 2013; 13:10–18.

6. Frieri M. Mast cell activation syndrome. Clin Rev Allergy Immunol. 2018; 54:353–365.

7. Hamilton MJ. Nonclonal mast cell activation syndrome: a growing body of evidence. Immunol Allergy Clin North Am. 2018; 38:469–481.

8. Valent P, Akin C. Doctor, I think I am suffering from MCAS: differential diagnosis and separating facts from fiction. J Allergy Clin Immunol Pract. 2019; 7:1109–1114.

9. Castells M, Butterfield J. Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management. J Allergy Clin Immunol Pract. 2019; 7:1097–1106.

10. Valent P, Bonadonna P, Hartmann K, et al. Why the 20% + 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome. Int Arch Allergy Immunol. 2019; 180:44–51.